For time-to-event data with finitely many competing risks, the proportional hazards model has been a popular tool for relating the cause-specific outcomes to covariates (Prentice and others, 1978. The analysis of failure time in the presence of competing risks. Biometrics 34, 541-554). Inspired by previous research in HIV vaccine efficacy trials, the cause of failure is replaced by a continuous mark observed only in subjects who fail. This article studies an extension of this approach to allow a multivariate continuum of competing risks, to better account for the fact that the candidate HIV vaccines tested in efficacy trials have contained multiple HIV sequences, with a purpose to elicit multiple types of immune response that recognize and block different types of HIV viruses. We develop inference for the proportional hazards model in which the regression parameters depend parametrically on the marks, to avoid the curse of dimensionality, and the baseline hazard depends nonparametrically on both time and marks. Goodness-of-fit tests are constructed based on generalized weighted martingale residuals. The finite-sample performance of the proposed methods is examined through extensive simulations. The methods are applied to a vaccine efficacy trial to examine whether and how certain antigens represented inside the vaccine are relevant for protection or anti-protection against the exposing HIVs.
INTRODUCTION
Around 30 years ago, Prentice and others (1978) developed the mark-specific proportional hazard (PH) model for discrete marks, and since then a great deal of work has been done in discrete-mark failure time analysis, cf., Kalbfeisch and Prentice (1980) , Sun (2001) and Scheike and others (2008) . Alternatively, Huang and Louis (1998) first considered a continuous mark and developed the nonparametric maximum likelihood estimator of the joint distribution of the failure time and the mark. Motivated by applications in preventative HIV vaccine randomized placebo-controlled efficacy trials, Gilbert and others (2004, 2008) developed procedures for testing dependence of mark-specific hazards rates and relative risks (RRs) on the mark variable. Sun and others (2009) developed estimation and hypothesis testing methods for the mark-specific PH model with a univariate continuous mark. The mark variable of interest is a measure of the protein sequence distance between an HIV sequence sampled from a volunteer infected in the trial, to an HIV sequence represented inside the tested vaccine construct. As such, the scientific question is if and how the vaccine's effect to reduce the hazard of HIV acquisition depends on the sequence distance mark; answers to this question may guide vaccine development, as discussed extensively in the above-cited papers and elsewhere.
However, the previous work did not account for multivariate marks. This is a serious limitation given that all of the candidate HIV vaccines tested in HIV vaccine efficacy trials have contained multiple antigens/immunogens, with rational to attempt to elicit multiple types of immune response that recognize and block different types of HIV viruses. The greater the number of virus types that can be recognized and killed by vaccine-induced immune responses, the greater the potential overall vaccine efficacy. In the first two efficacy trials, the HIV vaccine construct contained two Envelope (Env) protein antigens, based on two distinct strains of HIV, such that a two-dimensional mark variable is of interest (Flynn and others, 2005; Pitisuttithum and others, 2006) . The vaccine construct evaluated in the third and fourth efficacy trials contained Gag, Pol, and Nef protein antigens, making a three-dimensional mark variable of interest (Buchbinder and others, 2008; Gray and others, 2009) . Lastly, the fifth and most recent efficacy trial tested a vaccine that contained Gag, Pol, and Nef protein antigens, as well as three distinct Env protein antigens, making a six-dimensional mark variable of interest (Rerks-Ngarm and others, 2009) .
The previous work dealt with the multivariate mark issue by collapsing the multiple distances from an infected subject into a univariate mark-the minimum of the distances to each vaccine antigen. This approach is reasonable under the premise that the only thing that matters for protection is the nearness of the exposing HIV to the closest antigen represented inside of the vaccine (e.g. Gilbert and others, 2008) . However, there are many ways in which this assumption may fail. For example, based on host genetics (e.g. HLA type or Fc-γ -receptor type), one subgroup may be protected through immune responses that recognize HIV peptides that are similar to HIV peptides represented in antigen 1, whereas another subgroup may be protected through immune responses that are similar to HIV peptides represented in antigen 2; in this case, the vaccine efficacy depends on both individual distances and less so on the minimum distance. For a second example, there are many ways to define a protein sequence distance to be putatively immunologically relevant [several distances were used in the sequence analysis of the Buchbinder and others (2008) efficacy trial reported in Rolland and others (2011)] , and if two distances are used such that the first considers many HIV sites irrelevant for protection whereas the second sagely restricts attention to key HIV sites that are contained in epitopes that cause protection, then the first distance could be shorter even though vaccine efficacy depends only on the second. Therefore, a more general approach to assessing and modeling how vaccine efficacy depends on multiple sequence distances is needed, which does not pre-assume a particular way to collapse the multivariate distances into a univariate distance. Outside of the survival analysis field, Gilbert (2000) studied such a general approach with multivariate marks, based on a semiparametric biased sampling model. However, this method is limited by the fact that the model conditions on infection, so that conditional odds ratios but not prospective RRs of infection can be estimated, and 62
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by the fact that the model treats HIV infection as a binary outcome, not accounting for the time to HIV infection.
Let λ(t, v|z) be the conditional mark-specific hazard function, defined as λ (t, v|z) 
where T is the failure time, V is a continuous mark variable, and Z (t) is a time-dependent p-dimensional covariate. Sun and others (2009) studied the markspecific PH model
for evaluating the mark-specific vaccine efficacy. Under this model, the ratio of hazard functions for any two individuals is a function of the mark independent of time. This assumption may not always be met in practice, and can be relaxed through stratification (Dabrowska, 1997) . Here we propose to study the stratified mark-specific PH model with multivariate marks where the baseline hazard function can vary with stratum. Under the stratified mark-specific PH model, the ratio of hazard functions for any two individuals within same stratum is independent of time. However, it may be time dependent for two individuals from different strata. For simplicity, we consider a two-dimensional mark variable v = (v 1 , v 2 ). The methods for general multivariate mark follow a similar outline. Note that the mark-specific RR function
Estimation of β(v) without any structural assumptions is possible following the procedure for one-dimensional mark variable by Sun and others (2009) . However, this would require a very large sample size due to the curse of dimensionality. In this paper, we consider a parametric model for β(v) as the first-order Taylor approximation of β(v) plus an interaction term that allows investigation of the effects of both marks as well as the interactions. We develop an estimation procedure for the stratified mark-specific PH model under this parametric structure for β (v) . We also develop some testing procedures examining how the vaccine efficacy depends on the marks and how relevant the two marks are for protection against HIV infection. The goodness of fit of the proposed model is tested based on the generalized weighted martingale residuals. The rest of the paper is organized as follows. In Section 2, we develop a partial likelihood procedure for estimating β (v) . The asymptotic properties of the proposed estimator are derived. Likelihood-based statistical tests are proposed to examine a variety of null hypotheses to understand whether and how the vaccine efficacy depends on the marks. In Section 3, we propose a procedure for testing goodness of fit of the multivariate mark-specific proportional hazard model based on the generalized weighted martingale residuals. The proposed methods are applied to a vaccine efficacy trial in Section 4. Extensive simulations are conducted to examine the finite sample performance of the proposed methods in Section 5. Proofs of the main results are placed in the supplementary material available at Biostatistics online.
MARK-SPECIFIC PH MODEL WITH MULTIVARIATE MARKS

Mark-specific PH model
Let λ k (t, v|z) be the conditional mark-specific hazard function at time t with mark v for a subject in stratum k with covariate z (Sun and others, 2009) . We assume that the mark V takes value in the interval [0, 1] 2 , rescaled if necessary. The stratified multivariate mark-specific PH model speculates that 
where each of β 0 , β 1 , β 2 , and β 12 is a p-dimensional vector. Thus β(v) is completely specified by the 4 × p parameters denoted byβ = (β
T , where z 1 is the vaccine group indicator, with z 1 = 1 for the vaccine group and z 1 = 0 for the placebo group, while z 2 (t) is other possibly time-dependent covariates. Under the mark-specific PH model (2.1), the mark-specific RR is
is the coefficient corresponding z 1 . The markspecific vaccine efficacy VE(v) = 1 − RR(v) represents the percentage reduction for the vaccine versus placebo in risk of failure at time t with mark v after adjusting for covariates z 2 . It does not depend on time t under model (2.1).
Let T k be the failure time for an individual in the kth stratum, V k be the mark observed at failure and Z k be the associated p-dimensional covariate. Assume that
Under right censoring, the observed random variables are
and C k is the censoring random variable, which is assumed to be independent of
Let τ be the end of follow-up time, where failure times beyond τ are considered censored. The estimation of model (2.1) for β(v) under parametric structure (2.2) is given next.
Estimation of the mark-specific PH model
Let N ki (t, v) = I (X ki t, V ki v, δ ki = 1) be the marked counting process for ith individual in stratum k, where the relation V ki v indicates that the inequality holds for each component of the multivariate mark. Let Y ki (t) = I (X ki t) be the at-risk process. Under (2.2), β(v) is completely specified bȳ
⊗v with ⊗ being the Kronecker product. Similar to Kalbfleisch and Prentice (1980) for the competing risks model with finite number of causes, the log-partial likelihood function forβ can be expressed as
The maximum partial likelihood estimator (MPLE)β forβ is obtained by maximizing l(β) given in (2.4). Taking the derivative of l(β) with respect toβ, the score function can be written as
where
Here for a vector z, 
The information matrix is the derivative of U (β) with respect toβ given as
The MPLEβ forβ is the solution to U (β) = 0. Under condition 1 in Section 2.3, the matrix I (β) is positive definite with probability 1 as n k → ∞ for 1 k K . Thusβ exists almost surely and is unique for large sample sizes. The baseline function λ 0k (t, v) can be estimated by smoothing the increments of the following estimator of the doubly cumulative baseline function 0k (t, v 
are kernel functions, and h 1 and h 2 are the corresponding bandwidths. The cause-related cumulative
Asymptotic results
Letβ 0 be the true value ofβ under models (2.1) and (2.2). Let s
We make use of the following regularity conditions. Condition 1. The covariate process Z k (t) is left continuous with bounded variation and satisfies the moment condition sup 0 t τ E{ Z k (t) 4 exp(M Z k (t) )} < ∞, where · is the Euclidean norm and M is a positive constant such that (β
where B is an neighborhood ofβ 0 .
The asymptotic results forβ andˆ 0k (·, ·), 1 k K , are presented in the following theorems.
THEOREM 2.1 Under conditions 1-3,β converges in probability toβ 0 as n → ∞.
THEOREM 2.3 Under conditions 1-3, the following decomposition holds uniformly in
. . , K , with the latter being asymptotically independent mean-zero Guassian random fields with variances s, u) ds du and with independent increments.
Hypothesis testing
We propose some statistical tests for evaluating whether and how the vaccine efficacy depends on the marks. The following null hypotheses are examined: H 10 : is defined in (2.6). The score test statistic is given by
, where the score function U (β H 0 ) and information matrix I (β) are defined in (2.5) and (2.6), respectively. Routine analysis following Serfling (1980) shows that under H 0 , T l , T w , and T s converge in distribution to a chi-square distribution with degrees of freedom equal to the number of parameters specified under H 0 . The LRT rejects H 10 if T l > χ The tests can be carried out for the hypotheses that only concern a single component of the coefficients to examine how one particular covariate effect is modified by the marks.
GOODNESS-OF-FIT TESTS
The estimation and testing procedures developed in Section 2 are developed under model (2.1) with β(v) having the parametric structure (2.2). The validity of these procedures depends on goodness of fit of the multivariate mark-specific proportional hazard model. This section develops some goodness-of-fit tests of model (2.1) under the parametric structure (2.2) for β(v) following Lin and others (1993) 
We derive the model checking test 
whereβ is the MPLE given in Section 2, andˆ 0k (t, v) is defined in (2.7).M ki (t, v) may be interpreted as the difference up to time t between the observed and the predicted number of events with marks at failures less than v for the ith subject in kth stratum. Thus the martingale residuals are informative about model misspecifications. It is easy to check that 
3)
The distribution of S under the null hypothesis is complicated and intractable. To calculate the critical value of the proposed test statistic, we consider using the Guassian multiplier method (Lin and others, 1993) that can be applied to approximate the distribution of the process W (t, v, z). The key step toward the application of this method is to approximate W (t, v, z) with the sum of iid processes as shown next.
, where A ⊗ B is the Kronecker product of matrices A and B. Let s (t, v, z,β) }. The proof of the following decomposition is given in the supplementary material at Biostatistics online.
THEOREM 3.1 Assume conditions 1-3. For 1 k K , we have
as n → ∞ where
Expression (3.4) shows that the process W k (t, v, z) is asymptotically equivalent to the sum of iid terms involving the integrations with respect to M li (s, u) . Donsker's theorem (cf., van der Vaart, 1998) on the weak convergence of empirical processes can be used to show that the process W (t, v, z) = (W 1 (t, v, z) , . . . , W K (t, v, z) ) converges weakly to a multi-dimensional Gaussian random field.
Let {ξ li , i = 1, . . . , n l , l = 1, . . . , K } be iid standard normal random variables. For 1 k K , let
Following an application of Sun and Wu (2005, Lemma 1), the distribution of W (t, v, z) can be approximated by the conditional distribution of
given the observed data sequence. The continuous mapping theorem entails that the distribution of S can be approximated by the empirical distribution of S * = sup 1 k K sup t,v,z |W * k (t, v, z)| obtained through repeatedly generating independent sets of {ξ li , i = 1, . . . , n l , l = 1, . . . , K } while holding the observed data fixed. We reject model (2.1) under the parametric structure (2.2) for β(v) at the significance level α if S is greater than the critical value S α -the upper α quantile of the copies of S * described above.
APPLICATION TO A VACCINE EFFICACY TRIAL
We now illustrate our methods with the analysis of data from a vaccine efficacy trial conducted in North and South America (Buchbinder and others, 2008) . The '
Step' trial randomized 1836 HIV-negative men to receive either the Merck Adenovirus 5 (Ad5) vaccine (MRKAd5) or placebo. Women were also enrolled, but only one became HIV infected. Of the 1836 men, 87 acquired HIV infection. The sequencing labs attempted to derive single-genome-amplification HIV sequences from all 87 subjects, and were only successful for 65. The 22 men with no sequence data were excluded from the analysis, and therefore for the method to provide consistent estimation the missing completely at random (MCAR) assumption is needed. While MCAR seems reasonable in the application (partial support comes from an analysis of the predictors of missing sequence data, which uncovered no significant predictors), it cannot be assured. Sun and Gilbert (2012) developed an augmented inverse probability-weighted approach to provide consistent estimation and inference in the mark-specific proportional hazards model under a missing at random (MAR) assumption, but this method considered only a univariate mark variable. It would be of interest to extend their method to the multivariate mark setting. Alternatively, it would be of interest to extend the multiple imputation approach of Lu and Tsiatis (2001) from the discrete mark setting to the continuous mark setting. The randomization was stratified by whether a volunteer had pre-existing immunity to the Ad5 vector that was used in the vaccine, defined by an Ad5 neutralization titer greater than 200. The method is implemented accounting for these two strata, where 1058 (778) volunteers had Ad5 below (above) 200. In the data analysis, we focus on men only.
For those with Ad5 200, there were 54 total infections: 29 of 522 in the vaccine group (with 7 missing marks) and 25 of 536 in the placebo group (with 8 missing marks). The annual incidences were 5.6% for the vaccine group and 4.7% for the placebo group. For Ad5 > 200, there were 33 total infections: 24 of 392 in the vaccine group (with 7 missing marks) and 9 of 386 infections in the placebo group (with 0 missing marks). The annual incidences were 6.1% for the vaccine group and 2.3% for the placebo group.
Two factors motivate the need to consider multiple protein sequence distances for the sieve analysis (Gilbert, 2000) . First, the MRKAd5 vaccine contained three HIV-1 proteins: Gag, Pol, and Nef. Each of these proteins stimulates immune responses in vaccine recipients that could plausibly make the vaccine effect on infection vary with genetic distance to the protein. As a control, it is also of interest to evaluate genetic distances to all of the HIV-1 vaccine proteins combined not included in the vaccine, Env-Rev-TatVif-Vpr-Vpu, for which the central HXB2 reference strain was used. Because the vaccine should not be able to stimulate immune responses to these proteins, it is expected that the vaccine effect on infection would not vary with this control genetic distance. Secondly, as described in greater detail in the clinical paper (Rolland and others, 2011) , two different bioinformatics methods, NetMHC (Buus and others, 2003) and Epipred (Heckerman and others, 2007) , were used to predict, for each infected subject, the set of HIV peptides in the reference sequence that could potentially bind to at least one of his/her HLA alleles. These peptides are the ones that could potentially constitute T-cell epitopes and hence contribute to a vaccine effect on infection.
NetMHC predicts quantitative binding of peptides to four-digit HLA alleles, whereas Epipred identifies known and potential HIV-1 CTL epitope motifs using two-digit HLA information. In addition to the known HLA-restricted epitopes previously reported at the Los Alamos National Laboratory HIV database (HIVDB), we accepted all epitope motifs with a posterior probability of > 0.8. HLA-specific epitopes were predicted in the Gag-Pol-Nef protein sequence contained in the tested vaccine (the 'Step' reference sequence) and in all proteins from the HXB2 reference sequence (available at the HIVDB, http:www.hiv.lanl.gov). Using Epipred, the first step in computing the distance between a subject's sequences and the reference sequence is to compute the nonparametric maximum likelihood estimate (NPMLE) of the number of peptides shared between the reference sequence and the subject's sequences, defined as the sum of estimated epitope-probabilities across all 8-, 9-, 10-, 11-mers in the reference sequence that are exactly matched in all of the subject's sequences. Then, the distance is the NPMLE of the percent of peptides mismatched in at least one of the subject's sequences, defined as one minus the ratio of the NPMLE of the number of shared peptides (computed in the first step) and the NPMLE of the number of peptides in the reference sequence. Because the NetMHC software categorizes quantitative binding readouts as nonbinder, weak binder, or strong binder, we defined the distance as the estimated percent of epitopes mismatched in at least one of the subject's sequences, the latter defined as the number of weak or strong binding 8-, 9-, 10-, or 11-mers in the reference sequence that mismatch the corresponding peptide in at least one of the subject's sequences.
We consider distances defined using the reference HIV-1 regions Gag, Pol, Nef, Env-Rev-Tat-VifVpr-Vpu, as well as using the two bioinformatics prediction methods. The five selected marks, {v j , j = 1, . . . , 5}, are listed in Table 1 . We analyze the data with the mark-specific proportional hazards model (2.1), where the covariate z is the indicator for the treatment, with z = 1 for the vaccine group and 0 for placebo group. The K = 2 strata are the Ad5 200 and Ad5 > 200 groups. We use the standardized marks in the analysis, which are obtained by subtracting the minimum and dividing the range of the measurements for each mark. We perform the backwards model selection procedure by starting the analysis with all five marks in the model (2.1) with β(v) = β 0 + Because the overall infection rate was higher in the vaccine than placebo group (Cox model RR = 1.50, 95% CI 0.95-2.41, p = 0.06 ), we estimate the mark-specific RR as RR(v 1 , v 2 ) = exp(β 1 (v 1 , v 2 ) ) instead of the mark-specific vaccine efficacy; thus for the step trial the analysis focuses on whether and how the vaccine selectively increased the susceptibility to HIV infection. Based on the β point estimates, the estimated RR, R R(v 1 , v 2 ) (its standard error), equals 3.27 (3.14), 0.91 (1.63), and 3.08 (11.21) for (v 1 , v 2 ) = (0.2,0.2), (0.5, 0.5), and (0.8, 0.8), respectively. Hence the 95% confidence intervals for R R(v 1 , v 2 ) is (−2.88, 9.42), (−2.28, 4.10), and (−18.89, 25 .05) at (v 1 , v 2 ) = (0.2,0.2), (0.5, 0.5), and (0.8, 0.8), respectively. The interpretation is that the vaccine had no effect on infection against HIV-1 when both distances are in the range from 0.2 to 0.8.
SIMULATION STUDY
Numerical performance of estimation and hypothesis testing procedures
In this section, we conduct a simulation study to examine finite sample properties of the proposed estimation and hypothesis testing procedures. The simulations are set up to mimic the step data from the HIV vaccine efficacy trial conducted in North and South America (Buchbinder and others, 2008) . We take K = 2 strata corresponding to two levels of neutralization titer Ad5. Two sample sizes n k = 250 and 400 are considered for each stratum. The baseline hazard functions λ 0k (t, v) are set as constants λ 0k , with λ 01 = 0.4 and λ 02 = 0.6. The covariate Z k is a Bernoulli random variable with Z k = 1 corresponding to the vaccine group and Z k = 0 for the placebo group. We take P(Z k = 1) = 0.5. The censoring time C k follows an exponential distribution, independent of (T k , V k ). We consider the following selections of (β 0 , β 1 , β 2 , β 12 ) under (2.1) and (2.2) to examine the proposed estimation and hypothesis testing procedures: Here M 10 is a model under the null hypothesis H 10 which states that β(v) does not depend on either mark v 1 or v 2 . Under M 11 , the mark-specific RR depends on both marks but not the interaction of these marks. Under M 12 , the mark-specific RR depends on both marks and their interaction. M 20 is a model under the null hypothesis H 20 where only β 12 is zero, and M 30 is a model under the null hypothesis H 30 where β(v) does not depend on v 2 . The overall RRs of the vaccine versus the placebo in most of the settings are around 50%. The percentage of censoring in all settings is about 70% at the end of follow-up τ = 2. Table 3 lists the bias, the sample standard error of the estimates (SSE), the average of the estimated standard errors (ESE), and the coverage probability (CP) for β for sample size n k = 250 and 400. Table 3 shows that the biases of the estimators are small, ESE approximates SSE well, and the coverage probabilities are very close to their nominal level of 0.95. 
